Psychodrama for Adults With Relapsing-Remitting Multiple Sclerosis: A Mixed-Methods Study
Key facts
- Where
- Mersin, TürkiyeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07928765, who can take part
Where in Türkiye
- Mersin University Faculty of Medicine, Department of Neurology, Demyelinating Diseases UnitMersin, TürkiyeNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bahçeşehir University
- Trial code
- NCT07928765
- Record updated
- 10 November 2026
- Original description
This single-group, mixed-methods study explored changes following a 13-week group psychodrama programme in adults with relapsing-remitting multiple sclerosis (MS). Participants were recruited from the demyelinating diseases unit of Mersin University Hospital, Türkiye, and attended weekly sessions of approximately 180 minutes in addition to their standard medical treatment. Loneliness, fatigue, cognitive performance, depressive and anxiety symptoms, and sleep quality were assessed at baseline, after the intervention and at 6-month follow-up. Individual semi-structured interviews conducted after the intervention and at follow-up explored participants' experiences of physical, cognitive, psychological and social change. Quantitative and qualitative findings were integrated within a convergent mixed-methods design.Read full original descriptionShow less
Exploring Therapeutic Change Following Psychodrama in Multiple Sclerosis: A Mixed-Methods Study With 6-Month Follow-Up
This single-group, mixed-methods study explored changes following a 13-week group psychodrama programme in adults with relapsing-remitting multiple sclerosis (MS). Participants were recruited from the demyelinating diseases unit of Mersin University Hospital, Türkiye, and attended weekly sessions of approximately 180 minutes in addition to their standard medical treatment. Loneliness, fatigue, cognitive performance, depressive and anxiety symptoms, and sleep quality were assessed at baseline, after the intervention and at 6-month follow-up. Individual semi-structured interviews conducted after the intervention and at follow-up explored participants' experiences of physical, cognitive, psychological and social change. Quantitative and qualitative findings were integrated within a convergent mixed-methods design.
Inclusion: Diagnosis of relapsing-remitting multiple sclerosis, in remission; Age 18 to 65 years; Willingness to attend group sessions regularly; Written informed consent.
Exclusion: Acute psychiatric disorder; Hearing or speech impairment that would prevent group participation; Wheelchair dependence.